These are the stocks posting the largest moves before the bell.Market Insiderread more
Morgan Stanley analysts said the reduction was driven by concerns around Chinese demand for Tesla products.Autosread more
Alphabet Inc's Google said Tuesday that keeping phones up to date and secure was in "everyone's best interests," shortly after the U.S. temporarily eased some trade...Technologyread more
Technology stocks are a casualty of the trade war, but analysts say there's a chance longer term some companies might emerge stronger, depending on what kind of deal is...Market Insiderread more
Home Depot on Tuesday reported fiscal first-quarter earnings that beat analysts expectations, despite a damp start to the spring in much of the U.S.Retailread more
As tariff worries hit Apple, the stock has fallen into a bear market. But Joule Financial's Quint Tatro believes the pullback represents a buying opportunity, while...Trading Nationread more
American Airlines slashed fees for surf boards, skis and other oversize sports equipment as well as music gear. Rival United Airlines last year took a similar step cutting...Airlinesread more
Shares of chipmakers rebounded from a sell-off on Tuesday after the U.S. temporarily eased some trade restrictions on China's Huawei.Marketsread more
Stocks are weathering the latest bouts increasing trade fears, but the bond market is pointing to more trouble ahead.Marketsread more
June marks the start of Atlantic hurricane season, and after years of record damage from increasingly powerful storms, homeowners and builders are looking intensely at ways to...Rising Risksread more
Leuthold Group's Jim Paulsen sees a silver lining as the U.S.-China trade war rattles the market.Trading Nationread more
HERSHEY, Pa. and ROCKVILLE, Md., Aug. 28, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ( "ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that its Vice President of R&D, Teri Heiland, Ph.D., will be delivering an oral presentation on the company's LAMP-vax™ platform, along with one poster at the Skin Vaccination Summit in Lausanne, Switzerland on September 2-4.
The oral presentation, entitled, "'Immunization with ARA H-LAMP-vax peanut vaccine protects and blocks IgE-mediated anaphylaxis in a peanut allergic murine model," will be held on September 3, 2015 at 10:20 AM local time.
The poster, "Manufacture and Needle-Free, Intradermal Delivery of Antibiotic Free NTC RNA-Out™ LAMP-vax™ Plasmids,"was also co-authored by Dr. Heiland. The study demonstrates that intradermal administration of ITI's proprietary LAMP-vax formulation using a Biojector device showed improved generation of antibodies when compared to conventional injection.
"These presentations and posters represent significant advancement in the development LAMP-vax, particularly with regard to peanut allergies," said William Hearl, Ph.D., CEO of ITI. "As we continue to gather data regarding our technology and its application to treating peanut allergies, we are encouraged by what we are learning regarding the potential of our development programs. This work could allow for significant improvement in the lives of those who have suffered with allergies, particularly food allergies, with no viable solutions to date."
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. LAMP was exclusively licensed from Johns Hopkins University and has been studied in various areas, including oncology and infectious disease, while internally ITI is focused on developing allergy therapies. Currently, the company is pursuing three main allergy programs:
For more information about ITI and LAMP Technology, please visit www.immunomix.com.
CONTACT: Jules Abraham JQA Partners, Inc. 917-885-7378 firstname.lastname@example.orgSource:Immunomic Therapeutics, Inc.